Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.73 USD | -4.07% | -9.89% | +28.07% |
07:05pm | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.